Cancer Chemotherapy and Pharmacology

, Volume 63, Issue 2, pp 261–266 | Cite as

Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer

Original Article

Abstract

Purpose

Clinical trials have reported conflicting results as to whether pre-operative aromatase inhibitors (AIs) improve outcome over pre-operative tamoxifen in postmenopausal women with hormone receptor-positive breast cancer.

Methods

We performed a meta-analysis comparing primary and secondary end points of pre-operative AI and pre-operative tamoxifen. The event-based risk ratio (RR) with 95% confidence intervals (95% Cis) were derived, and a test of heterogeneity was applied.

Results

Four studies (1,160 patients) met the inclusion criteria for the analysis. Meta-analysis showed that pre-operative AI was more effective than pre-operative tamoxifen. Pooled results of clinical efficacy were as follows: clinical objective response rate (RR, 1.29; 95% CI, 1.14–1.47; P < 0.001), ultrasound objective response rate (RR, 1.29; 95% CI, 1.10–1.51; P = 0.002), and breast conserving surgery (BCS) rate (RR, 1.36; 95% CI, 1.16–1.59; < 0.001). Hot flashes, nausea, and fatigue were not different between the pre-operative AI and pre-operative tamoxifen groups. Although headache was more frequent in the pre-operative AI group (= 0.011), it was a manageable toxicity and was not clinically relevant.

Conclusion

Pre-operative AI has better BCS rate than tamoxifen and in terms of toxicities, is not inferior to tamoxifen; therefore, we could suggest pre-operative AI instead of tamoxifen for those postmenopausal patients with hormone receptor positive breast cancer, not eligible for chemotherapy.

Keywords

Meta-analysis Aromatase inhibitor Tamoxifen Pre-operative Breast cancer 

Notes

Acknowledgments

This work was supported in part by the Brain Korea 21 Project and the Korean Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (Grant no. 01-PG3-PG6-01GN07-0004).

References

  1. 1.
    Dixon JM, Anderson TJ, Miller WR (2002) Neoadjuvant endocrine therapy of breast cancer: a surgical perspective. Eur J Cancer 38:2214–2221PubMedCrossRefGoogle Scholar
  2. 2.
    Beresford MJ, Ravichandran D, Makris A (2007) Neoadjuvant endocrine therapy in breast cancer. Cancer Treat Rev 33:48–57PubMedCrossRefGoogle Scholar
  3. 3.
    Witherby SM, Muss HB (2006) Managing early-stage breast cancer in your older patients. Oncology (Williston Park) 20:1003–1012Google Scholar
  4. 4.
    Ferretti G, Bria E, Giannarelli D, Felici A, Papaldo P, Fabi A, Di Cosimo S, Ruggeri EM, Milella M, Ciccarese M, Cecere FL, Gelibter A, Nuzzo C, Cognetti F, Terzoli E, Carlini P (2006) Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials. Br J Cancer 94:1789–1796PubMedCrossRefGoogle Scholar
  5. 5.
    Mauri D, Pavlidis N, Plyzos NP, Ioannidis JPA (2006) Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 98:1285–1291PubMedCrossRefGoogle Scholar
  6. 6.
    Carlini P, Bria E, Giannarelli D, Ferretti G, Felici A, Papldo P, Fabi A, Nistico C, Di Cosimo S, Ruggeri EM, Milella M, Mottolese M, Teroli E, Cognetti F (2005) New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma. Cancer 104:1335–1342PubMedCrossRefGoogle Scholar
  7. 7.
    Gazet JC, Ford HT, Coombes RC, Bland JM, Sutcliffe R, Quilliam J, Lowndes S (1994) Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol 20:207–214PubMedGoogle Scholar
  8. 8.
    Mustacchi G, Milani S, Pluchinotta A, De Matteis A, Rubagotti A, Perrota A (1994) Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: the G.R.E.T.A. trial group for research on endocrine therapy in the elderly. Anticancer Res 14:2197–2200PubMedGoogle Scholar
  9. 9.
    Robertson JF, Ellis IO, Elston CW, Blamey RW (1992) Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. Eur J Cancer 28A:908–910PubMedCrossRefGoogle Scholar
  10. 10.
    Robinson E, Kimmick GG, Muss HB (1996) Tamoxifen in postmenopausal women a safety perspective. Drugs Aging 8:329–337PubMedCrossRefGoogle Scholar
  11. 11.
    Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802PubMedCrossRefGoogle Scholar
  12. 12.
    Cuppone F, Bria E, Verma S, Pritchard KI, Gandhi S, Carlini P, Milella M, Nistico C, Terzoli E, Cognetti F, Giannarelli D (2008) Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer 112:260–267PubMedCrossRefGoogle Scholar
  13. 13.
    Pritchard KI, Abramson BL (2006) Cardiovascular health and aromatase inhibitors. Drugs 66:1727–1740PubMedCrossRefGoogle Scholar
  14. 14.
    Gerber B, Krause A, Reimer T, Mylonas I, Makovitzky J, Kundt G, Janni W (2006) Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology. Clin Cancer Res 12:1245–1250PubMedCrossRefGoogle Scholar
  15. 15.
    Perez EA (2007) Safety of aromatase inhibitors in the adjuvant setting. Breast Cancer Res Treat 105(Suppl 1):75–89PubMedCrossRefGoogle Scholar
  16. 16.
    Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, Dube P, de Oliveira CT (2006) Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the pre-operative “Arimidex” compared to tamoxifen (PROACT) trial. Cancer 106:2095–2103PubMedCrossRefGoogle Scholar
  17. 17.
    Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12:1527–1532PubMedCrossRefGoogle Scholar
  18. 18.
    Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23:5108–5116PubMedCrossRefGoogle Scholar
  19. 19.
    Semiglazov V, Kletsel A, Semiglazov V, Shiltzova E, Ivanov V, Dashyan G et al (2005) Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER + breast cancer (T2N1–2, T3N0–1, T4N0M0). Proc Am Soc Clin Oncol 23:16SGoogle Scholar
  20. 20.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedCrossRefGoogle Scholar
  21. 21.
    Fisher B, Redmond C, Poisson R, Margolese R, Wolmark N, Wickerham L, Fisher E, Deutsch M, Caplan R, Pilch Y (1989) Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 320:822–828PubMedCrossRefGoogle Scholar
  22. 22.
    Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483–2493PubMedGoogle Scholar
  23. 23.
    Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV, Bear HD (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672–2685PubMedGoogle Scholar
  24. 24.
    Schick P, Goodstein J, Moor J, Butler J, Senter KL (1983) Preoperative chemotherapy followed by mastectomy for locally advanced breast cancer. J Surg Oncol 22:278–282PubMedCrossRefGoogle Scholar
  25. 25.
    Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, Dorval T, Palangie T, Jouve M, Beuzeboc P et al (1994) Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30A:645–652PubMedCrossRefGoogle Scholar
  26. 26.
    van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19:4224–4237PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Division of Medical Oncology, Department of Internal Medicine, College of MedicineKorea University Guro HospitalSeoulSouth Korea

Personalised recommendations